Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer

Niannian Ji, Meijun Long, Andreu Garcia-Vilanova, Russell Ault, Juan I. Moliva, Kizil A. Yusoof, Neelam Mukherjee, Tyler J. Curiel, Hong Dixon, Jordi B. Torrelles, Robert S. Svatek

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Purpose: Repeated instillations of bacillus Calmette et Guérin (BCG) are the gold standard immunotherapeutic treatment for reducing recurrence for patients with high-grade papillary non-muscle invasive bladder cancer (NMIBC) and for eradicating bladder carcinoma-in situ. Unfortunately, some patients are unable to tolerate BCG due to treatment-associated toxicity and bladder removal is sometimes performed for BCG-intolerance. Prior studies suggest that selectively delipidated BCG (dBCG) improves tolerability of intrapulmonary delivery reducing tissue damage and increasing efficacy in preventing Mycobacterium tuberculosis infection in mice. To address the lack of treatment options for NMIBC with BCG-intolerance, we examined if selective delipidation would compromise BCG’s antitumor efficacy and at the same time increase tolerability to the treatment. Materials and methods: Murine syngeneic MB49 bladder cancer models and in vitro human innate effector cell cytotoxicity assays were used to evaluate efficacy and immune impact of selective delipidation in Tokyo and TICE BCG strains. Results: Both dBCG-Tokyo and dBCG-TICE effectively treated subcutaneous MB49 tumors in mice and enhanced tumor-infiltrating CD8+ T and natural killer cells, similar to conventional BCG. However, when compared to conventional BCG, only dBCG-Tokyo retained a significant effect on intratumoral tumor-specific CD8+ and γδ T cells by increasing their frequencies in tumor tissue and their production of antitumoral function-related cytokines, i.e., IFN-γ and granzyme B. Further, dBCG-Tokyo but not dBCG-TICE enhanced the function and cytotoxicity of innate effector cells against human bladder cancer T24 in vitro. Conclusions: These data support clinical investigation of dBCG-Tokyo as a treatment for patients with BCG-intolerant NMIBC.

Original languageEnglish (US)
Pages (from-to)125-136
Number of pages12
JournalCancer Immunology, Immunotherapy
Issue number1
StatePublished - Jan 2023


  • BCG
  • Bladder cancer
  • Delipidation
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer'. Together they form a unique fingerprint.

Cite this